# Immunocore

Kimmtrak (tebentafusp), a soluble gp100 TCR-anti-CD3 bispecific for HLA-A02:01+ metastatic uveal melanoma, was reported in April 2026 to double the likelihood of being alive at five years — the first TCR-based bispecific approved.

Source: https://en.bioecon.ru/companies/immunocore/
Updated: 2026-07-11

- Country: United Kingdom
- Ticker: IMCR

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $864 million in cash and cash equivalents as of year-end 2025 | https://www.immunocore.com/investors/financials-filings/annual-reports/content/0001140361-26-015125/0001140361-26-015125.pdf |
| Capacity | outsourced to third-party contract manufacturing organizations (CMOs); company does not own or plan to build its own manufacturing capacity | https://www.nullexposure.com/suppliers/imcr |
| Production site | Denmark, Germany, and the Netherlands (final packaging) | https://www.immunocore.com/investors/financials-filings/sec-filings/content/0001671927-26-000005/0001671927-26-000005.pdf, https://www.nullexposure.com/suppliers/imcr |
| Headcount | 524 full-time employees as of December 31, 2025 | https://longbridge.com/en/news/276883036.md |
| Revenue | $400 million in net revenue for the fiscal year 2025 | https://www.immunocore.com/investors/financials-filings/annual-reports/content/0001140361-26-015125/0001140361-26-015125.pdf |
| Revenue | $106.7 million in net product revenue for the first quarter of 2026 | https://www.immunocore.com/investors/news/press-releases/detail/130/immunocore-reports-first-quarter-financial-results-and-provides-a-business-update |
| Regulatory approval | KIMMTRAK approved for metastatic uveal melanoma in 39 countries, including the United States, European Union, United Kingdom, Canada, and Australia | https://www.immunocore.com/investors/financials-filings/sec-filings/content/0001671927-26-000009/0001671927-26-000009.pdf, https://www.immunocore.com/investors/news/press-releases/detail/34/the-uk-medicines-and-healthcare-products-regulatory-agency-mhra-australian-therapeutic-goods-administration-tga-and-health-canada-approve-kimmtrak-tebentafusp-for-the-treatment-of-unresectable-or-metastatic-uveal-melanoma |

Independent sources: longbridge.com, nullexposure.com

## Technologies

- [TCR therapy (T-cell receptor engineered T cells)](https://en.bioecon.ru/technology/tcr-therapy/)